Abstract:Mitochondrial DNA (mtDNA) is a critical genome contained within the mitochondria of eukaryotic cells, with many copies present in each mitochondrion. Mutations in mtDNA often are inherited and can lead to severe health problems, including various inherited diseases and premature aging. The lack of efficient repair mechanisms and the susceptibility of mtDNA to damage exacerbate the threat to human health. Heteroplasmy, the presence of different mtDNA genotypes within a single cell, increases the complexity of these diseases and requires an effective editing method for correction. Recently, gene-editing techniques, including programmable nucleases such as restriction endonuclease, zinc finger nuclease, transcription activator-like effector nuclease, clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeats-associated 9 and base editors, have provided new tools for editing mtDNA in mammalian cells. Base editors are particularly promising because of their high efficiency and precision in correcting mtDNA mutations. In this review, we discuss the application of these techniques in mitochondrial gene editing and their limitations. We also explore the potential of base editors for mtDNA modification and discuss the opportunities and challenges associated with their application in mitochondrial gene editing. In conclusion, this review highlights the advancements, limitations and opportunities in current mitochondrial gene-editing technologies and approaches. Our insights aim to stimulate the development of new editing strategies that can ultimately alleviate the adverse effects of mitochondrial hereditary diseases.

Gene therapy for mitochondrial disorders

Beyond the membrane: Exploring non-viral methods for mitochondrial gene delivery

Research Progress in Mitochondrial Gene Editing Technology.

Current and Emerging Clinical Treatment in Mitochondrial Disease

The special considerations of gene therapy for mitochondrial diseases

Gene therapy restores mitochondrial function and protects retinal ganglion cells in optic neuropathy induced by a mito-targeted mutant ND1 gene

Development of mitochondrial gene-editing strategies and their potential applications in mitochondrial hereditary diseases: a review

Therapeutic potential of engineering the mitochondrial genome.

Current Clinical Applications of In Vivo Gene Therapy with AAVs

A Review over Mitochondrial Diseases Due to mtDNA Mutations: Recent Advances and Remedial Aspects

Applications of Gene Editing in Mitochondrial Diseases

Gene-based therapies for neuromuscular disorders

Therapeutic Approaches to Treat Mitochondrial Diseases: “One-Size-Fits-All” and “Precision Medicine” Strategies

Applications of Gene Therapy in Cardiomyopathies

Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care

Gene therapy for Leber hereditary optic neuropathy

In vivo mitochondrial base editing via adeno-associated viral delivery to mouse post-mitotic tissue

Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle

Mitochondrial genome editing: strategies, challenges, and applications

A Review of Gene Therapy in Cardiomyopathies

AAV-based in vivo gene therapy for neurological disorders